High-Quality STROMUSC Telmisartan(Micardis)40mg For Treat High Blood Pressure CAS:144701-48-4

    What Is Telmisartan?

    Telmisartan is a specific, selective angiotensin II receptor antagonist that targets the AT₁ receptor subtype. Angiotensin II, a potent vasoconstrictor, exerts its effects primarily through binding to AT₁ receptors located in vascular smooth muscle, the adrenal gland, and various other tissues. By displacing angiotensin II from these receptor sites, telmisartan effectively neutralizes the vasoconstrictor and aldosterone-releasing actions of this hormone.

    The chemical identity of telmisartan is precise: 4'-[(1,4'-dimethyl-2'-propyl[2,6'-bi-1H-benzimidazol]-1'-yl)-methyl]-[1,1'-biphenyl]-2-carboxylic acid, with a molecular formula of C₃₃H₃₀N₄O₂ and a molecular weight of 514.6. The compound presents as an off-white to yellowish crystalline powder with distinctive solubility characteristics-practically insoluble in water, very slightly soluble in ethanol, and soluble in chloroform-methanol mixtures. These physicochemical properties, particularly its high lipophilicity, contribute significantly to its extended duration of action and tissue distribution profile.

    What fundamentally distinguishes telmisartan from some other ARBs is its lack of partial agonist activity at the AT₁ receptor. This means that when telmisartan binds to the receptor, it blocks angiotensin II signaling without triggering any residual receptor activation-a clean, complete antagonism that ensures predictable and reliable blood pressure lowering.

    Pharmacological Selectivity

    Top-quality telmisartan demonstrates extraordinary receptor selectivity. It binds with very high affinity to the AT₁ receptor subtype while showing no relevant affinity for other receptor systems. This selectivity translates into a focused mechanism of action with minimal off-target effects-a hallmark of sophisticated drug design.

    Long-Lasting Receptor Binding

    The binding of telmisartan to the AT₁ receptor is remarkably long-lasting. This sustained receptor occupancy, combined with the drug's extended plasma half-life, ensures that a single daily dose provides continuous protection against angiotensin II-mediated vasoconstriction throughout the entire 24-hour dosing interval.

    High Lipophilicity and Tissue Distribution

    Telmisartan exhibits high lipophilicity, which facilitates extensive tissue distribution. The volume of distribution is approximately 500 liters, indicating significant tissue binding beyond the plasma compartment. This property contributes to the drug's prolonged pharmacological action and may underlie some of its beneficial effects beyond simple blood pressure reduction.

    Partial PPAR-γ Agonism

    Perhaps the most distinctive feature of telmisartan among ARBs is its partial agonist activity at peroxisome proliferator-activated receptor gamma (PPAR-γ). This nuclear receptor is involved in regulating glucose and lipid metabolism, and telmisartan's interaction with it confers metabolic benefits that extend beyond blood pressure control. This property positions telmisartan uniquely within its class, offering advantages for patients with metabolic syndrome or diabetes.

    Bioavailability and Formulation Quality

    The 40 mg tablet formulation is designed for consistent oral absorption. The absolute bioavailability is approximately 42% at the 40 mg dose, increasing to 58% at 160 mg. The tablets contain carefully selected excipients including magnesium stearate, meglumine, povidone, sodium hydroxide, and sorbitol, which ensure stability and reliable drug release. Top-quality products maintain stringent manufacturing standards that guarantee batch-to-batch consistency in both potency and dissolution characteristics.

    Essential Hypertension

    The primary and most common indication for telmisartan 40 mg is the treatment of essential hypertension in adults. The drug effectively reduces both systolic and diastolic blood pressure without affecting pulse rate. Clinical trials have demonstrated that telmisartan 40 mg once daily produces significant reductions in blood pressure, with one study showing decreases of approximately 14/9 mmHg. The antihypertensive efficacy is independent of gender or age, making it a versatile option across diverse patient populations.

    The onset of antihypertensive activity occurs gradually within 3 hours after the first dose. Maximum reduction in blood pressure is generally attained 4 to 8 weeks after the start of treatment and is sustained during long-term therapy. This gradual onset reflects the drug's mechanism of action and the time required for full therapeutic effect to manifest.

    Cardiovascular Risk Reduction

    Beyond hypertension management, telmisartan has a formal indication for reducing the risk of non-fatal stroke or non-fatal myocardial infarction in adults aged 55 years or older at high risk of developing major cardiovascular events who cannot tolerate an angiotensin-converting enzyme inhibitor.    For this indication, the recommended dose is 80 mg once daily. However, the 40 mg dose often serves as the starting point for titration in these high-risk patients, with dose escalation guided by blood pressure response and tolerability.

    Combination Therapy

    Telmisartan 40 mg can be used effectively in combination with other antihypertensive agents. Thiazide-type diuretics such as hydrochlorothiazide and calcium channel blockers such as amlodipine have been shown to produce additive blood pressure-lowering effects when combined with telmisartan. This flexibility allows clinicians to tailor treatment regimens to individual patient needs, achieving target blood pressures with lower doses of each component medication.

    Special Populations

    In geriatric patients, no dose adjustment is necessary. For patients with renal impairment, including those on hemodialysis, no dosage adjustment is required-a significant advantage given that telmisartan is not removed from blood by hemofiltration and is not dialyzable. However, in patients with mild to moderate hepatic impairment, the dose should not exceed 40 mg once daily, and administration requires caution.

    Superior 24-Hour Blood Pressure Control

    Telmisartan provides more effective control of blood pressure over the full 24-hour dosing interval compared with many other antihypertensive agents. The trough-to-peak ratio for 40-80 mg doses exceeds 70% for both systolic and diastolic blood pressure, indicating that the blood pressure-lowering effect is well maintained throughout the dosing interval. This is particularly relevant for mitigating early morning blood pressure surges, which are known to increase the risk of cerebrovascular events.

    Cardiovascular and Cerebrovascular Protection

    Real-world evidence from large cohort studies has demonstrated that telmisartan is associated with significantly lower risks of stroke, heart failure, and all-cause mortality compared to other ARBs. In one study of over 83,000 matched patients, telmisartan use was associated with a hazard ratio of 0.805 for stroke, 0.75 for heart failure, and 0.59 for all-cause mortality compared to other ARBs. These benefits were consistent across key subgroups including patients with diabetes, chronic kidney disease, and hyperlipidemia.

    Metabolic Advantages

    Telmisartan's partial PPAR-γ agonist activity confers meaningful metabolic benefits. The drug ameliorates insulin resistance and hypertriglyceridemia, thereby improving components of the metabolic syndrome. It reduces total cholesterol and low-density lipoprotein cholesterol levels. Research has also demonstrated that telmisartan improves insulin sensitivity through mechanisms independent of adipose tissue. These metabolic effects make telmisartan particularly valuable for hypertensive patients with concomitant metabolic disturbances.

    Organ Protection

    Clinical trials have shown that telmisartan treatment is associated with statistically significant reductions in proteinuria, including both microalbuminuria and macroalbuminuria, in patients with hypertension and diabetic nephropathy. The drug also reduces left ventricular mass and left ventricular mass index in patients with hypertension and left ventricular hypertrophy. These organ-protective effects reflect the drug's ability to block the deleterious actions of angiotensin II at the tissue level, extending benefits beyond simple hemodynamic changes.

    Favorable Adverse Effect Profile

    The adverse effect profile of telmisartan is remarkably favorable. The most common adverse events reported in hypertension trials-back pain, sinusitis, and diarrhea-occur at an incidence of 1% or greater. The drug does not inhibit angiotensin-converting enzyme (kininase II), the enzyme that degrades bradykinin, and therefore does not potentiate bradykinin-mediated adverse effects such as cough or angioedema. This distinguishes telmisartan from ACE inhibitors and contributes to better treatment adherence.

    Gradual Return to Baseline

    Upon abrupt cessation of treatment, blood pressure gradually returns to pre-treatment values over a period of several days without evidence of rebound hypertension. This property provides a margin of safety should patients miss doses or discontinue therapy, reducing the risk of hypertensive crises associated with abrupt withdrawal of some other antihypertensive agents.

    Starting Dose

    For the treatment of essential hypertension, the recommended starting dose is 40 mg once daily. Some patients may already benefit at a daily dose of 20 mg, though the 40 mg formulation provides a robust starting point for most individuals.

    Dose Titration

    In cases where the target blood pressure is not achieved with 40 mg daily, the dose can be increased to a maximum of 80 mg once daily. When considering dose escalation, it is essential to recognize that the maximum antihypertensive effect is generally attained 4 to 8 weeks after the start of treatment. Premature dose escalation before this time point may lead to unnecessary increases in medication burden.

    Administration Instructions

    Micardis tablets are for once-daily oral administration and should be swallowed whole with liquid. The tablets can be taken with or without food. Food slightly reduces the bioavailability of telmisartan-by approximately 6% with the 40 mg tablet-but this small reduction is not expected to cause a clinically meaningful decrease in therapeutic efficacy.

    Special Dosage Considerations

    For patients with mild to moderate hepatic impairment, the dose should not exceed 40 mg once daily. No dose adjustment is required for geriatric patients or those with renal impairment. The safety and efficacy of telmisartan in patients below 18 years of age have not been established.

    Missed Dose Management

    If a dose is missed, it should be taken as soon as remembered. However, if it is nearly time for the next dose, the missed dose should be skipped and the regular dosing schedule resumed. Double dosing should be avoided.

    Initiation Phase

    The first 4 to 8 weeks of telmisartan therapy constitute the initiation phase, during which the full antihypertensive effect gradually develops. Blood pressure should be monitored periodically during this period to assess response. For patients who do not achieve target blood pressure with 40 mg, dose escalation to 80 mg may be considered after this initial period.

    Maintenance Phase

    Once target blood pressure is achieved, the maintenance phase begins. Telmisartan therapy is typically continued long-term, as hypertension is a chronic condition requiring ongoing management. The drug's excellent tolerability profile supports sustained use without the need for drug holidays or cycling.

    Duration of Therapy

    Hypertension treatment with telmisartan is generally life-long. There is no finite "cycle" as one might see with medications used for acute conditions. The benefits of blood pressure control-reduction in stroke, myocardial infarction, and other cardiovascular events-accrue over years of sustained treatment. Discontinuation should only occur under medical supervision, with gradual dose reduction if clinically indicated.

    Monitoring Parameters

    Regular monitoring during telmisartan therapy should include blood pressure measurements, assessment of renal function, and evaluation for potential adverse effects. In patients with diabetes, glucose and lipid profiles may also be monitored, given the drug's metabolic effects.

    Absorption

    Following oral administration, peak plasma concentrations of telmisartan are reached within 0.5 to 1 hour after dosing. The pharmacokinetics are nonlinear over the dose range of 20 mg to 160 mg, with greater than proportional increases in plasma concentrations with increasing doses.

    Distribution

    Telmisartan is highly bound to plasma proteins, with binding exceeding 99.5%, primarily to albumin and α1-acid glycoprotein. The volume of distribution is approximately 500 liters, indicating extensive tissue binding.

    Metabolism

    Telmisartan is metabolized by conjugation to form a pharmacologically inactive acyl glucuronide. The cytochrome P450 isoenzymes are not involved in its metabolism, reducing the potential for drug-drug interactions through this pathway. After a single dose, the glucuronide represents approximately 11% of the measured radioactivity in plasma.

    Elimination

    The terminal elimination half-life of telmisartan is approximately 24 hours. Total plasma clearance exceeds 800 mL/min. More than 97% of the administered dose is eliminated unchanged in feces via biliary excretion, with only minute amounts found in the urine (0.91% and 0.49% of total radioactivity, respectively). Terminal half-life and total clearance appear to be independent of dose.

    Steady-State Characteristics

    With once-daily dosing, telmisartan has an accumulation index in plasma of 1.5 to 2.0. Trough plasma concentrations are approximately 10% to 25% of peak plasma concentrations. This pharmacokinetic profile supports once-daily administration while maintaining meaningful receptor blockade throughout the dosing interval.

    Duration of Action

    An 80 mg dose of telmisartan almost completely inhibits the angiotensin II-evoked blood pressure increase, with the inhibitory effect maintained over 24 hours and still measurable up to 48 hours. This extended duration of action is a key differentiator from many other antihypertensive agents.

    Contextual Clarification

    It is important to clarify that Post-Cycle Therapy (PCT) is a concept derived from the field of performance-enhancing drug use, particularly anabolic steroid cycles. Telmisartan is a prescription medication for hypertension and cardiovascular risk reduction, not a performance-enhancing substance. The concept of PCT does not apply to telmisartan therapy in any conventional medical sense.

    Discontinuation of Telmisartan

    When telmisartan is discontinued for clinical reasons-such as switching to another antihypertensive agent or managing adverse effects-it should be done under medical supervision. Unlike some medications that require tapering to prevent withdrawal phenomena, telmisartan can generally be discontinued without risk of rebound hypertension. Blood pressure gradually returns to pre-treatment values over several days.

    Transition to Other Agents

    If a patient is transitioning from telmisartan to another antihypertensive agent, the new medication is typically initiated while the telmisartan is still being taken, with overlap to ensure continuous blood pressure control. The specific transition strategy depends on the pharmacological properties of both agents and the patient's clinical status.

    Monitoring After Discontinuation

    After telmisartan is discontinued, blood pressure should be monitored to ensure that alternative therapy adequately controls hypertension. Patients who discontinue telmisartan without initiating alternative therapy should have their blood pressure checked regularly, as hypertension will generally return to pre-treatment levels.

    No "Restoration" Required

    Unlike anabolic steroids, which suppress endogenous hormone production and require PCT to restore natural function, telmisartan does not suppress any endogenous system that requires "restoration." The renin-angiotensin-aldosterone system, which telmisartan modulates, returns to its baseline state upon drug discontinuation without requiring any specific recovery protocol.

Brand	STROMUSC
Trade names	Telmisartan;Micardis
CAS	144701-48-4
Molar mass	514.629
MF	C33H30N4O2
Purity	Above 98%
Apprarance	40mg*100

 

 

Any needs, please contact us

Email: Jasonraws106@gmail.com

WhatsApp: +86-15572565525
Telegram: +86-15871669785

   

                                  

 

    Telmisartan 40 mg (Micardis) represents a sophisticated and highly effective approach to the management of hypertension. Its unique combination of pharmacological properties-selective AT₁ receptor antagonism, long half-life, high lipophilicity, partial PPAR-γ agonist activity, and favorable metabolic effects-distinguishes it within the ARB class and makes it a preferred choice for many patients.

    The 40 mg formulation serves as the optimal starting dose for most patients, providing meaningful blood pressure reduction while allowing for individualized dose titration. The drug's excellent tolerability profile, with common adverse events limited to back pain, sinusitis, and diarrhea at low incidence rates, supports long-term use.

    Clinical evidence consistently demonstrates that telmisartan provides superior 24-hour blood pressure control and is associated with reduced risks of stroke, heart failure, and all-cause mortality compared to other ARBs. These benefits extend beyond simple blood pressure lowering, reflecting the drug's pleiotropic effects on metabolism, endothelial function, and organ protection.

    For healthcare providers and patients alike, telmisartan 40 mg offers a well-established, evidence-based option for hypertension management that balances efficacy, safety, and convenience. Its once-daily dosing, lack of significant food interactions, and favorable pharmacokinetic profile support adherence and therapeutic success. As our understanding of hypertension and its complications continues to evolve, telmisartan's unique properties position it as a cornerstone therapy for the foreseeable future.

Hot Tags: high-quality stromusc telmisartan(micardis)40mg for treat high blood pressure cas:144701-48-4, China high-quality stromusc telmisartan(micardis)40mg for treat high blood pressure cas:144701-48-4 manufacturers, suppliers, factory